Metabolomics of the Dietary Approaches to Stop Hypertension (DASH) Dietary Pattern

Johns Hopkins Bloomberg School of Public Health459 enrolled

Overview

The present record represents a secondary data analysis of the Dietary Approaches to Stop Hypertension (DASH) trial. Study data and specimens were accessed through the National Heart, Lung, and Blood Institute (NHLBI) Biologic Specimen and Data Repository Coordinating Center (BioLINCC). A global, untargeted, metabolomic profile was used to investigate biomarkers of the DASH dietary pattern as well as blood pressure change.

The present study was conducted in order to: 1) quantify the metabolomic expression of the DASH dietary pattern; and 2) examine the relationship between metabolites that reflect the DASH dietary pattern and blood pressure change. This secondary data analysis leverages the completed DASH trial, a randomized feeding trial (N=459).

Study Type

OBSERVATIONAL

Enrollment

459

Conditions

Dietary Modification Blood Pressure

Interventions

DASH dietBEHAVIORAL

Diet intervention

Fruits and vegetables dietBEHAVIORAL

Diet intervention

Control dietBEHAVIORAL

Diet intervention

Eligibility

Sex: ALLMin age: 22 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women with systolic blood pressure \<160 mmHg and diastolic blood pressure 80-95 mmHg Exclusion Criteria: * Taking anti-hypertensive medication * Poorly controlled diabetes mellitus * Hyperlipidemia * Cardiovascular event within the past 6 months * Chronic disease that may interfere with participation * Pregnancy or lactation * Body mass index \> 35 kg/m2 * Unwilling to stop taking vitamin or mineral supplements or antacids * Kidney disease * Consumption of \>14 alcoholic beverages per week * Did not consent to the use of biological specimens * Did not attend the 8 week follow-up visit * No serum specimen or insufficient volume of serum specimens in repository

Outcomes

Primary Outcomes

Serum metabolites

Metabolites were measured using a global, untargeted, metabolomic platform in serum specimens collected at the end of the 8 week diet intervention in the DASH trial. Reverse phase, untargeted ultrahigh-performance liquid chromatography tandem mass spectrometry quantification was used to measure metabolites. Peaks were quantified by calculating the area under the curve. Data were normalized to account for day-to-day instrumental variation. Compounds were identified by comparison to a library of purified standards or recurrent unknown entities and matches were determined based on retention time, mass-to-charge ratio, and chromatographic data. A relative measure of each metabolite (not absolute) is determined. The Metabolon (Durham, NC) platform quantifies over 1,000 compounds representing a broad range of metabolic compounds, including amino acids, carbohydrates, cofactors and vitamins, energy, lipids, nucleotides, peptides, and xenobiotics (chemicals, drugs, and food components).

Time frame: 8 week follow-up visit

Secondary Outcomes

Blood pressure

The change in blood pressure was defined as the blood pressure level at the end of the 8 week diet intervention minus the blood pressure level at baseline.

Time frame: 8 week follow-up visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.